This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Betriu, C.
Right arrow Articles by Picazo, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Betriu, C.
Right arrow Articles by Picazo, J. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2004, p. 323-325, Vol. 48, No. 1
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.1.323-325.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

In Vitro Activities of Tigecycline against Erythromycin-Resistant Streptococcus pyogenes and Streptococcus agalactiae: Mechanisms of Macrolide and Tetracycline Resistance

C. Betriu,* E. Culebras, I. Rodríguez-Avial, M. Gómez, B. A. Sánchez, and J. J. Picazo

Department of Clinical Microbiology, Hospital Clínico San Carlos, 28040 Madrid, Spain

Received 26 July 2003/ Returned for modification 19 August 2003/ Accepted 26 September 2003


arrow
ABSTRACT
 
The activity of tigecycline was tested against erythromycin-resistant streptococci (107 Streptococcus pyogenes and 98 Streptococcus agalactiae strains). The presence of erythromycin and tetracycline resistance genes was determined by PCR. Among S. pyogenes strains the most prevalent gene was mef(A) (91.6%). The erm(B) gene was the most prevalent (65.3%) among S. agalactiae strains. Tigecycline proved to be very active against all the isolates tested (MIC at which 90% of the isolates tested were inhibited, 0.06 µg/ml), including those resistant to tetracycline.


arrow
INTRODUCTION
 
An increased incidence of macrolide resistance among beta-hemolytic streptococci has been reported in several countries during the past 2 decades (1, 5, 6, 11, 18). Every day, fewer therapeutic options for penicillin-allergic patients are available. The present rates of erythromycin resistance in our area of Spain are about 30% for Streptococcus pyogenes (3) and 18% for Streptococcus agalactiae (2). Tigecycline (formerly GAR-936) is a novel glycylcycline antibiotic that was shown to have potent activity against a wide spectrum of gram-positive and gram-negative bacteria, including strains resistant to other antimicrobials (4, 8, 10, 13). The purpose of this study was to evaluate the in vitro activities of tigecycline and comparator agents against macrolide-resistant S. pyogenes and S. agalactiae. The mechanisms of macrolide and tetracycline resistance have also been determined.

A total of 107 S. pyogenes and 98 S. agalactiae isolates resistant to erythromycin were included, regardless of their resistance to tetracycline. Organisms were collected at the Hospital Clínico San Carlos during the period 1994 to 2001. The sources of S. pyogenes isolates were the upper respiratory tract (93 isolates), skin and soft tissues (8 isolates), vagina (4 isolates), blood (1 isolate), and cerebrospinal fluid (1 isolate). The 98 S. agalactiae isolates were recovered from the following sources: skin and soft tissues (51 isolates), urine (24 isolates), vagina (11 isolates), abdomen (5 isolates), blood (4 isolates), and upper respiratory tract (3 isolates). Organisms were identified by standard methods, including agglutination with latex (Slidex Strepto A and Slidex Strepto B; bioMérieux, Marcy l'Etoile, France). Only one isolate per patient was studied to avoid duplication.

Susceptibility was tested by the agar dilution method according to the National Committee for Clinical Laboratory Standards (12) with Mueller-Hinton agar supplemented with 5% sheep blood. The plates were incubated overnight at 35°C in ambient air. The MIC was defined as the lowest antibiotic concentration that completely inhibits the growth of the organism as detected by the unaided eye. The preliminary breakpoints of tigecycline are <=2 µg/ml for susceptibility, 4 µg/ml for intermediate status, and >=8 µg/ml for resistance (7). Streptococcus pneumoniae ATCC 49619 and Staphylococcus aureus ATCC 29213 were used as control strains. The following antimicrobial agents were included in the study: tigecycline (Wyeth Pharmaceuticals, Philadelphia, Pa.), erythromycin (Abbott Laboratories S.A., Madrid, Spain), clindamycin (Pharmacia S.A., Barcelona, Spain), quinupristin-dalfopristin (Aventis Pharma S.A., Madrid, Spain), penicillin (Cepa Schwarz Pharma S.L., Madrid, Spain), and minocycline and tetracycline (Sigma-Aldrich Química S.A., Madrid, Spain).

Determination of macrolide resistance phenotypes was performed by the double-disk method (15). The presence of erythromycin resistance genes was determined by PCR (16). The DNAs of the erythromycin-resistant isolates were amplified with primers specific for the erm(A), erm(B), and mef(A) genes. The PCR conditions for the primer sets were as described previously (9, 16). DNA preparation and electrophoresis of PCR products were carried out by established procedures (9, 16). The 14 S. pyogenes and 88 S. agalactiae isolates resistant to tetracycline were tested for the presence of tetracycline resistance genes tet(M), tet(O), tet(K), and tet(L) by PCR as described by Trzcinski et al. (17).

The results of the susceptibility studies are shown in Table 1. The resistance rate for tetracycline among S. agalactiae isolates was 89.8%, while among S. pyogenes this rate was 13.1%. Quinupristin-dalfopristin had excellent activity (MIC at which 90% of the isolates tested were inhibited, 0.5 µg/ml). All isolates tested were exquisitely susceptible to penicillin, and penicillin MIC ranges for S. pyogenes were slightly lower than those for S. agalactiae.


View this table:
[in this window]
[in a new window]
  		TABLE 1. In vitro activity of tigecycline compared with those of other agents against 205 erythromycin-resistant streptococci

Tigecycline demonstrated similar in vitro activities against S. pyogenes and S. agalactiae. The new glycylcycline tested had better activities than did the comparative antibiotics, except penicillin, against most resistant organisms. Tigecycline, based on comparison of MICs at which 90% of the isolates were inhibited, was 12 to 14 times more active than minocycline and 4 to 8 times more active than quinupristin-dalfopristin against both streptococcal species tested. Our results agree with those described previously by several authors (7, 8, 10, 13), despite the fact that they studied a smaller number of streptococcal isolates.

Tigecycline is known to overcome the two major determinants of tetracycline resistance, ribosomal protection and active efflux (13, 19). In our study, no differences in the activities of tigecycline between the tetracycline-susceptible and tetracycline-resistant streptococcal isolates tested were noted. Tetracycline-resistant S. agalactiae and S. pyogenes strains were inhibited by <=0.25 and <=0.06 µg/ml of tigecycline, respectively.

The distribution of erythromycin and tetracycline resistance genes is shown in Table 2. The constitutive macrolide-lincosamide-streptogramin B resistance (cMLSB) phenotype was observed in 9.3% of S. pyogenes and 68.4% of S. agalactiae isolates. Strains with the M phenotype accounted for 82.3 and 6.1% of S. pyogenes and S. agalactiae isolates, respectively.


View this table:
[in this window]
[in a new window]
  		TABLE 2. Distribution of erythromycin and tetracycline resistance genes among 205 erythromycin-resistant streptococci

PCR of the macrolide resistance determinants in S. pyogenes isolates detected mef(A) in 89 isolates and erm(B) in 9 isolates. Both mef(A) and erm(A) were found in 10 isolates. The 88 M-phenotype isolates harbored the mef(A) gene, and nine of them also had the erm(A) gene. Erythromycin resistance in one constitutive-phenotype isolate was not associated with either the mef or the erm gene.

Among S. agalactiae strains, the erm(B) gene was the most prevalent (in 65.3% of isolates) followed by erm(A) (59.2%). The erm(A) gene was found in 37 cMLSB phenotype isolates, in 18 isolates with the inducible MLSB phenotype, and in 3 M-phenotype isolates. Twenty-seven isolates possessed both erm(A) and erm(B) determinants.

We also investigated the molecular basis of tetracycline resistance. The majority (76.5%) of tetracycline-resistant streptococcal isolates included in the study harbored tet(M), which confers resistance to both tetracycline and minocycline. The 12 S. pyogenes isolates resistant to tetracycline have been found to be positive only for tet(M). Of the 88 tetracycline-resistant S. agalactiae isolates, 66 (75%) carried the tet(M) gene and 19 (21.6%) carried the tet(O) gene. In five tetracycline-resistant isolates (two of S. pyogenes and three of S. agalactiae), none of the tetracycline resistance genes tested were found. Isolates carrying both tet(M) and tet(O) genes, as Poyart et al. (14) recently reported, were not detected in our study. Neither the tet(L) nor the tet(K) gene was found in the present study.

The potent activity of tigecycline against all the strains tested, irrespective of their phenotype of resistance to erythromycin or their resistance to tetracycline, indicates that this agent could be considered an alternative to penicillin for the treatment of infections caused by erythromycin-resistant S. pyogenes and S. agalactiae.


arrow
ACKNOWLEDGMENTS
 
This work was supported by grant CAM 08.2/0005/1999.1 from the Comunidad Autónoma de Madrid and by grant FIS PI0 20037 from the Fondo de Investigación Sanitaria, Madrid, Spain.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Department of Clinical Microbiology, Hospital Clínico San Carlos, Plaza Cristo Rey s/n, 28040 Madrid, Spain. Phone: 34 913303486. Fax: 34 913303478. E-mail: cbetriu{at}efd.net. Back


arrow
REFERENCES
 
    1
  1. Betriu, C., M. C. Casado, M. Gómez, A. Sánchez, M. L. Palau, and J. J. Picazo. 1999. Incidence of erythromycin resistance in Streptococcus pyogenes: a 10-year study. Diagn. Microbiol. Infect. Dis. 33:255-260.[CrossRef][Medline]
    2. 2
  2. Betriu, C., E. Culebras, M. Gómez, I. Rodríguez-Avial, B. A. Sánchez, M. C. Ágreda, and J. J. Picazo. 2003. Erythromycin and clindamycin resistance and telithromycin susceptibility in Streptococcus agalactiae. Antimicrob. Agents Chemother. 47:1112-1114.[Abstract/Free Full Text]
    3. 3
  3. Betriu, C., E. Culebras, M. Redondo, I. Rodríguez-Avial, M. Gómez, A. Boloix, and J. J. Picazo. 2002. Prevalence of macrolide and tetracycline resistance mechanisms in Streptococcus pyogenes isolates and in vitro susceptibility to telithromycin. J. Antimicrob. Chemother. 50:436-438.[Free Full Text]
    4. 4
  4. Betriu, C., I. Rodríguez-Avial, B. A. Sánchez, M. Gómez, J. Álvarez, J. J. Picazo, and Spanish Group of Tigecycline. 2002. In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain. Antimicrob. Agents Chemother. 46:892-895.[Abstract/Free Full Text]
    5. 5
  5. Cornaglia, G., M. Ligozzi, A. Mazzariol, L. Masala, G. Lo Cascio, G. Orefici, R. Fontana, et al. 1998. Resistance of Streptococcus pyogenes to erythromycin and related antibiotics in Italy. Clin. Infect. Dis. 27(Suppl. 1):S87-S92.
    6. 6
  6. De Azavedo, J. C., R. H. Yeung, D. J. Bast, C. L. Duncan, S. B. Borgia, and D. E. Low. 1999. Prevalence and mechanisms of macrolide resistance in clinical isolates of group A streptococci from Ontario, Canada. Antimicrob. Agents Chemother. 43:2144-2147.[Abstract/Free Full Text]
    7. 7
  7. Deshpande, L. M., A. C. Gales, and R. N. Jones. 2001. GAR-936 (9-t-butylglycylamido-minocycline) susceptibility test development for streptococci, Haemophilus influenzae and Neisseria gonorrhoeae: preliminary guidelines and interpretive criteria. Int. J. Antimicrob. Agents 18:29-35.[Medline]
    8. 8
  8. Gales, A. C., and R. N. Jones. 2000. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates. Diagn. Microbiol. Infect. Dis. 36:19-36.[CrossRef][Medline]
    9. 9
  9. Kataja, J., H. Seppälä, M. Skurnik, H. Sarkkinen, and P. Huovinen. 1998. Different erythromycin resistance mechanisms in group C and group G streptococci. Antimicrob. Agents Chemother. 42:1493-1494.[Abstract/Free Full Text]
    10. 10
  10. Milatovic, D., F.-J. Schmitz, J. Verhoef, and A. C. Fluit. 2003. Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrob. Agents Chemother. 47:400-404.[Abstract/Free Full Text]
    11. 11
  11. Morales, W. J., S. S. Dickey, P. Bornick, and D. V. Lim. 1999. Change in antibiotic resistance of group B Streptococcus: impact on intrapartum management. Am. J. Obstet. Gynecol. 181:310-314.[CrossRef][Medline]
    12. 12
  12. National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A5, vol. 20. National Committee for Clinical Laboratory Standards, Wayne, Pa.
    13. 13
  13. Petersen, P. J., N. V. Jacobus, W. J. Weiss, P. E. Sum, and R. T. Testa. 1999. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob. Agents Chemother. 43:738-744.[Abstract/Free Full Text]
    14. 14
  14. Poyart, C., L. Jardy, G. Quesne, P. Berche, and P. Trieu-Cuot. 2003. Genetic basis of antibiotic resistance in Streptococcus agalactiae strains isolated in a French hospital. Antimicrob. Agents Chemother. 47:794-797.[Abstract/Free Full Text]
    15. 15
  15. Seppälä, H., A. Nissinen, Q. Yu, and P. Huovinen. 1993. Three different phenotypes of erythromycin-resistant Streptococcus pyogenes in Finland. J. Antimicrob. Chemother. 32:885-891.[Free Full Text]
    16. 16
  16. Sutcliffe, J., T. Grebe, A. Tait-Kamradt, and L. Wondrack. 1996. Detection of erythromycin-resistant determinants by PCR. Antimicrob. Agents Chemother. 40:2562-2566.[Abstract]
    17. 17
  17. Trzcinski, K., B. S. Cooper, W. Hryniewicz, and C. G. Dowson. 2000. Expression of resistance to tetracyclines in strains of methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 45:763-770.[Abstract/Free Full Text]
    18. 18
  18. Uh, Y., I. H. Jang, G. Y. Hwang, K. J. Yoon, and W. Song. 2001. Emerging erythromycin resistance among group B streptococci in Korea. Eur. J. Clin. Microbiol. Infect. Dis. 20:52-54.[CrossRef][Medline]
    19. 19
  19. Van Ogtrop, M. L., D. Andes, T. J. Stamstad, B. Conklin, W. J. Weiss, W. A. Craig, and O. Vesga. 2000. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. Antimicrob. Agents Chemother. 44:943-949.[Abstract/Free Full Text]

Antimicrobial Agents and Chemotherapy, January 2004, p. 323-325, Vol. 48, No. 1
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.1.323-325.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Brown, S. D., Traczewski, M. M. (2007). Comparative In Vitro Antimicrobial Activity of Tigecycline, a New Glycylcycline Compound, in Freshly Prepared Medium and Quality Control. J. Clin. Microbiol. 45: 2173-2179 [Abstract] [Full Text]  
  • Kasbekar, N. (2006). Tigecycline: A new glycylcycline antimicrobial agent.. Am J Health Syst Pharm 63: 1235-1243 [Abstract] [Full Text]  
  • Kronvall, G., Karlsson, I., Walder, M., Sorberg, M., Nilsson, L. E. (2006). Epidemiological MIC cut-off values for tigecycline calculated from Etest MIC values using normalized resistance interpretation. J Antimicrob Chemother 57: 498-505 [Abstract] [Full Text]  
  • Breedt, J., Teras, J., Gardovskis, J., Maritz, F. J., Vaasna, T., Ross, D. P., Gioud-Paquet, M., Dartois, N., Ellis-Grosse, E. J., Loh, E., for the Tigecycline 305 cSSSI Study Group, (2005). Safety and Efficacy of Tigecycline in Treatment of Skin and Skin Structure Infections: Results of a Double-Blind Phase 3 Comparison Study with Vancomycin-Aztreonam. Antimicrob. Agents Chemother. 49: 4658-4666 [Abstract] [Full Text]  
  • Pankey, G. A. (2005). Tigecycline. J Antimicrob Chemother 56: 470-480 [Abstract] [Full Text]  
  • Muralidharan, G., Fruncillo, R. J., Micalizzi, M., Raible, D. G., Troy, S. M. (2005). Effects of Age and Sex on Single-Dose Pharmacokinetics of Tigecycline in Healthy Subjects. Antimicrob. Agents Chemother. 49: 1656-1659 [Abstract] [Full Text]  
  • Duarte, R. S., Bellei, B. C., Miranda, O. P., Brito, M. A. V. P., Teixeira, L. M. (2005). Distribution of Antimicrobial Resistance and Virulence-Related Genes among Brazilian Group B Streptococci Recovered from Bovine and Human Sources. Antimicrob. Agents Chemother. 49: 97-103 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Betriu, C.
Right arrow Articles by Picazo, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Betriu, C.
Right arrow Articles by Picazo, J. J.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»